Results 41 to 50 of about 24,684 (197)

Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme [PDF]

open access: yes, 2014
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Peer reviewedPublisher ...
A D Morris   +36 more
core   +7 more sources

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

open access: yesPLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira   +5 more
doaj   +1 more source

Prevalence of age-related macular degeneration in Nakuru, Kenya: a cross-sectional population-based study. [PDF]

open access: yes, 2013
BACKGROUND: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries.
Bastawrous, Andrew   +5 more
core   +6 more sources

The results of comparative analysis of angiogenic and laser therapy for diabetic macular edema in diabetes type 2

open access: yesOftalʹmologiâ, 2014
Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.Methods: The progress of visual acuity, retinal thickness and light sensivity after laser ...
I. V. Vorobieva   +4 more
doaj   +3 more sources

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

open access: yesInternational Journal of Retina and Vitreous, 2019
Background ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor. This study evaluated the effect of ASP8232 on excess retinal thickness when given alone or in combination with ranibizumab in patients with center ...
Quan Dong Nguyen   +10 more
doaj   +1 more source

Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia [PDF]

open access: yesInternational Journal of Ophthalmology, 2017
AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. METHODS: Study
Nur Afiqah Mohamad   +9 more
doaj   +1 more source

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

open access: yes, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto   +5 more
core   +1 more source

Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. [PDF]

open access: yesPLoS ONE, 2014
OBJECTIVE: To evaluate if a standardized combination therapy regimen, utilizing 3 monthly ranibizumab injections followed by navigated laser photocoagulation, reduces the number of total ranibizumab injections required for treatment of diabetic macular ...
Raffael Liegl   +8 more
doaj   +1 more source

Análise Retrospetiva Sobre a Utilização em Contexto Real do Ranibizumab em Doentes com Degenerescência Macular da Idade Exsudativa em Portugal [PDF]

open access: yes, 2017
INTRODUCTION: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice ...
Canelas, J   +8 more
core   +3 more sources

Home - About - Disclaimer - Privacy